In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Acelyrin Inc (NASDAQ: SLRN) closed at $5.01 in the last session, up 2.66% from day before closing price of $4.88. In other words, the price has increased by $2.66 from its previous closing price. On the day, 2.37 million shares were traded. SLRN stock price reached its highest trading level at $5.1748 during the session, while it also had its lowest trading level at $4.74.
Ratios:
We take a closer look at SLRN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.65 and its Current Ratio is at 8.65. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on December 13, 2023, initiated with a Equal Weight rating and assigned the stock a target price of $11.
On December 08, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $8.
Morgan Stanley Downgraded its Overweight to Equal-Weight on September 13, 2023, while the target price for the stock was maintained at $19.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 01 ’24 when Lin Shao-Lee sold 9,961 shares for $6.63 per share. The transaction valued at 66,024 led to the insider holds 1,577,374 shares of the business.
Lin Shao-Lee sold 15,701 shares of SLRN for $119,403 on Feb 20 ’24. The Chief Executive Officer now owns 1,587,335 shares after completing the transaction at $7.60 per share. On Jan 02 ’24, another insider, Lin Shao-Lee, who serves as the Chief Executive Officer of the company, sold 10,691 shares for $7.41 each. As a result, the insider received 79,188 and left with 1,603,036 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLRN now has a Market Capitalization of 492808672 and an Enterprise Value of -227103104.
Stock Price History:
Over the past 52 weeks, SLRN has reached a high of $29.88, while it has fallen to a 52-week low of $4.76. The 50-Day Moving Average of the stock is -31.12%, while the 200-Day Moving Average is calculated to be -58.26%.
Shares Statistics:
According to the various share statistics, SLRN traded on average about 1.25M shares per day over the past 3-months and 893440 shares per day over the past 10 days. A total of 97.87M shares are outstanding, with a floating share count of 61.01M. Insiders hold about 37.98% of the company’s shares, while institutions hold 68.12% stake in the company. Shares short for SLRN as of 1711584000 were 7948477 with a Short Ratio of 6.36, compared to 1709164800 on 6927249. Therefore, it implies a Short% of Shares Outstanding of 7948477 and a Short% of Float of 10.24.
Earnings Estimates
The stock of Acelyrin Inc (SLRN) is currently drawing attention from 4 analysts actively involved in the ongoing evaluation and rating process.On average, analysts expect EPS of -$0.92 for the current quarter, with a high estimate of -$0.8 and a low estimate of -$1.01, while EPS last year was -$8.61. The consensus estimate for the next quarter is -$0.93, with high estimates of -$0.82 and low estimates of -$1.05.
Analysts are recommending an EPS of between -$3.22 and -$4.2 for the fiscal current year, implying an average EPS of -$3.74. EPS for the following year is -$4.36, with 5 analysts recommending between -$3.11 and -$6.26.
